Gilead Sciences Inc
Change company Symbol lookup
Select an option...
GILD Gilead Sciences Inc
NMZ Nuveen Municipal High Income Opportunity Fund
TPGS TPG Pace Solutions Corp
SP SP Plus Corp
RDW Redwire Corp
BCAUY Brilliance China Automotive Holdings Ltd
RBC Regal Beloit Corp
WTRG Essential Utilities Inc
GRX Gabelli Healthcare & WellnessRx Trust
MILEW Metromile Inc *W EXP 02/09/2026
Go

Health Care : Biotechnology | Large Cap Value
Company profile

Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.

Price
Delayed
$71.23
Day's Change
-0.46 (-0.64%)
Bid
--
Ask
--
B/A Size
--
Day's High
71.87
Day's Low
71.21
Volume
(Light)

Today's volume of 1,791,374 shares is on pace to be much lighter than GILD's 10-day average volume of 7,285,867 shares.

1,791,374

Display:

Providers:

UpdateCancel
4 providers
Yesterday's News, September 23, 2021
Gilead Sciences Inc. Stock Rises Thursday, Still Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Gilead Sciences Inc. (GILD) inched 0.43% higher to $71.69 Thursday, on what proved to be an all-around favorable trading session...(MarketWatch)

September 22, 2021
Gilead Sciences Inc. Stock Underperforms Wednesday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Gilead Sciences Inc. (GILD) slipped 0.49% to $71.38 Wednesday, on what proved to be an all-around great trading session for the...(MarketWatch)

September 21, 2021
Gilead Sciences Inc. Stock Outperforms Market On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Gilead Sciences Inc. (GILD) advanced 1.09% to $71.73 Tuesday, on what proved to be an all-around poor trading session for the stock...(MarketWatch)

September 20, 2021
Gilead Sciences Inc. Stock Falls Monday, Still Outperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Gilead Sciences Inc. (GILD) shed 0.91% to $70.96 Monday, on what proved to be an all-around grim trading session for the stock...(MarketWatch)

September 17, 2021
Gilead Sciences Inc. Stock Outperforms Market On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Gilead Sciences Inc. (GILD) inched 0.39% higher to $71.61 Friday, on what proved to be an all-around grim trading session for the...(MarketWatch)

September 16, 2021
Gilead Sciences Inc. Stock Falls Thursday, Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Gilead Sciences Inc. (GILD) dropped 0.60% to $71.33 Thursday, on what proved to be an all-around poor trading session for the stock...(MarketWatch)

September 15, 2021
Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Gilead Sciences Inc. (GILD) advanced 1.86% to $71.76 Wednesday, on what proved to be an all-around positive trading session for the...(MarketWatch)

September 14, 2021
Gilead Sciences Inc. Stock Outperforms Competitors On Strong Trading Day

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Gilead Sciences Inc. (GILD) inched 0.01% higher to $70.45 Tuesday, on what proved to be an all-around grim trading session for the...(MarketWatch)

Merck CEO: Authorization of its experimental antiviral COVID-19 treatment could come by year end

Merck & Co. Inc. (MRK) said it expects the company's experimental oral antiviral treatment for COVID-19 could get emergency authorization by the end of the year. "We expect to be able to see clinical data here in the back half of the year...(MarketWatch)

September 13, 2021
Gilead Sciences Inc. Stock Rises Monday, Still Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Gilead Sciences Inc. (GILD) inched 0.23% higher to $71.15 Monday, on what proved to be an all-around positive trading session for...(MarketWatch)

September 10, 2021
Gilead Sciences Inc. Stock Rises Friday, Outperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Gilead Sciences Inc. (GILD) inched 0.54% higher to $70.99 Friday, on what proved to be an all-around dismal trading session for the...(MarketWatch)

September 09, 2021
Gilead Sciences Inc. Stock Falls Thursday, Underperforms Market

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of Gilead Sciences Inc. (GILD) slipped 1.77% to $70.61 Thursday, on what proved to be an all-around grim trading session for the stock...(MarketWatch)

August 13, 2021
Rand Paul reveals his wife invested in remdesivir parent company Gilead Sciences at the start of the pandemic

By Weston Blasi Congressional members are required to disclose stock trades within 45 days. Rand Paul's reporting came 16 months late. Sen. Rand Paul (R-Ky.) revealed Wednesday that his wife purchased up to $15,000 worth of stock in...(MarketWatch)

July 29, 2021
Sales of Gilead's COVID-19 drug top $800 million

Claudia Assis Gilead Sciences Inc. late Thursday swung to a quarterly profit and reported rising sales thanks to its COVID-19 drug, but a revenue drop from two of its HIV drugs and ongoing concerns about the pandemic dragged the stock...(MarketWatch)

July 19, 2021
BioNTech to buy T-cell receptor facility and platform from Gilead Sciences

Shares of BioNTech SE (BNTX) were down 2.4% in premarket trading on Monday after the company said it plans to buy one of Gilead Sciences Inc.'s (GILD) clinical manufacturing facilities and its platform for T-cell receptor therapies. The...(MarketWatch)

June 24, 2021
Arcus stock jumps 19% after announcing it will move forward with trial for lung-cancer treatment

Shares of Arcus Biosciences Inc. (RCUS) gained 19.8% in trading on Thursday, the day after the company said its experimental lung-cancer PD-L1 treatment demonstrated clinical activity in an open-label, Phase 2 clinical study. Arcus did not...(MarketWatch)

June 21, 2021
30 states likely to miss President Biden's July 4 vaccination goal, and Brazil death toll tops 500,000

Ciara Linnane South Africa is suffering through a third wave of cases with no signs of a slowdown The U.S. is getting close to President Joe Biden's goal of having 70% of the adult population receive at least one vaccine dose by July...(MarketWatch)

Gilead says real-world data show COVID-19 drug Veklury can reduce the risk of death

Shares of Gilead Sciences Inc. (GILD) gained 0.3% in premarket trading on Monday after the drug manufacturer said retrospective research shows that Veklury, its COVID-19 treatment, reduces mortality among people who have been hospitalized with...(MarketWatch)

June 17, 2021
Looking for hedges against inflation? Try Apple, Nike, Verizon and stocks with this in common, strategists say

By Jack Denton Critical information for the U.S. trading day Stocks are set for a poor performance on Thursday, as markets absorb the Federal Reserve's indication...(MarketWatch)

June 05, 2021
Here's what AMC Entertainment's monster stock surge 'memes' for ETFs

By Mark DeCambre Welcome back! We hope you had a good Memorial Day holiday. It has been a fairly busy stretch for exchange-traded products this week, the surge in shares of "meme" stocks...(MarketWatch)

Next >

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.